Moss Genomics (FRA:F73) 5-Year EBITDA Growth Rate: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Moss Genomics 5-Year EBITDA Growth Rate?

Moss Genomics FRA:F73 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026.

Moss Genomics's EBITDA per Share for the three months ended in Mar. 2026 was €0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 2.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Moss Genomics was 2.40% per year. The lowest was 2.40% per year. And the median was 2.40% per year.

Moss Genomics  (FRA:F73) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Moss Genomics 5-Year EBITDA Growth Rate Related Terms

FRA:F73 vs VEEV, BTSG, TEM: 5-Year EBITDA Growth Rate Comparison

For the Health Information Services subindustry, Moss Genomics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moss Genomics 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Moss Genomics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Moss Genomics's 5-Year EBITDA Growth Rate falls into.


Moss Genomics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Moss Genomics (FRA:F73) has a 5-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Moss Genomics and its competitors.
Is Moss Genomics' 5-Year EBITDA Growth Rate too high?
Moss Genomics' current 5-Year EBITDA Growth Rate is 0.00%.
How does Moss Genomics' 5-Year EBITDA Growth Rate compare to VEEV and BTSG?
Moss Genomics' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Moss Genomics and its competitors. Moss Genomics's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moss Genomics stock overvalued right now?
Moss Genomics (FRA:F73) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Moss Genomics (FRA:F73), the current 5-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moss Genomics Business Description

Other Exchanges MOSS:Canada
Address 1030 West Georgia Street, Suite 907, Vancouver, BC, CAN, V6E 2Y3
Moss Genomics Inc is an emerging consumer genomics company that provides personalized health, anti-aging, and wellness solutions based on genomic, microbiome, and epigenome data. It aims to eliminate barriers in healthcare by offering accessible, affordable at-home testing along with easy-to-understand actionable results.